Internet of Events
Leaderboard
Traders
Markets
Hot Bets
Surveillance
Pricing
Log in
Get Access
Accrue
/
Home
/
Manifold Markets
/
Will a novel therapeutic/device which confers a survival benefit for glioblastoma be FDA approved by EOY 2028?
Manifold
Active
BINARY · cpmm-1
Will a novel therapeutic/device which confers a survival benefit for glioblastoma be FDA approved by EOY 2028?
Yes
51%
Yes Pool
$590
No Pool
$610